James, it certainly could react in the manner you suggest...and I would be very pleased to see it do so. My reason for such a conservative estimate is based on the fact that "none" of the events that were supposed to boost the pps has done so. Approvals and launches in Europe, re-acquiring US rights, quarter over quarter growth in sales. It's my contention that the only thing that will make the pps grow at this stage, based on its poor always declining performance over the years, is actual "sustained" profitability of the company, and the belief that the company can be successful either standing alone on its own merits, or sold based on its value to another company.
For this to occur, and depending on the always cryptically spoke of and elusive milestone payments, real growth in Europe and a successful launch of Vitaros in the US would have to occur...imho. The days of rocketing pps in biopharm based on speculation, and especially for Apricus, is not in play these days.
I suspect at some point, if Vitaros is profitable, the company will acquire other drugs like they did with Fispemifine or look to develop other drugs combing them with the skin permeation enhancer.
Who knows, the mere suggestion that a topical treatment for ED could make it to the US market, could set off a frenzy for APRI shares...that would be fantastic. In the meantime, I hunkered down for the long haul to see if Apricus can achieve sustained profitability. |
